To date, first phase II trials using the survivin antagonist YM155, a small molecule that acts by inhibiting survivin promoter activity, was well tolerated by patients with prostate cancer and diffuse large B-cell lymphoma proposing this compound to be combined with other cytotoxic drugs [50], [51], [52]. This evidence concerns the gene BIRC5 and diffuse large B-cell lymphoma.